Effects of anti TNF α antibody (infliximab) plus MTX on SCID-HuRAg-pit model

我们已经建立了SCID-HuRAg-PIT模型，即牙本质切片植入类风湿关节炎(RA)滑膜组织到SCID小鼠的背部。在本研究中，我们观察了英夫利昔单抗或英夫利昔单抗加甲氨蝶呤(MTX)对SCID-HuRAg-PIT模型的影响。英夫利昔单抗采用渗透压泵给药。甲氨蝶呤每周口服3次。对照组给予人免疫球蛋白。移植后4周取移植滑膜组织，测量凹陷形成情况。同时检测血浆肿瘤坏死因子-α、白介素6水平。英夫利昔单抗组大鼠血浆中肿瘤坏死因子-α和白介素6浓度明显降低。然而，关于牙本质上凹坑形成的数量还没有显著的发现。英夫利昔单抗与甲氨蝶呤联合用药时，牙本质上的窝洞形成数有显著差异。提示抗肿瘤坏死因子-α抗体与甲氨蝶呤联合应用对抑制骨破坏有一定作用。

We already developed SCID-HuRAg-pit model which is dentin slice are engrafted with rheumatoid arthritis (RA) synovial tissues on back of SCID mice.In this study, we investigate effects of infliximab alone or infliximab plus methotrexate (MTX) for SCID-HuRAg-pit model. Administration of infliximab was using by osmotic pump. Methotrexate was administered orally 3 times per week. Control group was administrated human IgG. The engrafted synovial tissues were taken 4 weeks after transplantation and measured pit-formation. Moreover, plasma TNF-a, IL-6 were also measured. Plasma TNF-a and IL-6 concentrations were decreased in the group of infliximab administrated. However, there is no significant finding on the number of pit-formation on dentin. On the other hand, in case of infliximab plus MTX were significant differences about the number of pit-formation on dentin. These results suggest that the anti TNF-α antibody and MTX combination was useful against inhibition of bone destruction.